Skip to main content

Table 2 Efficacy of rituximab on clinical and biologic parameters of nine SSc patients treated with anti-CD20 during the follow up

From: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

 

Baseline

After 3

Months

After 6

Months

After 12

months*

After 18

months**

After 24

months***

After 36

months****

Rodnan skin score

       

(mean (SD))

21.1 (9.0)

15.2 (6.0)

12.0 (6.1)

7.0 (4.0)

7.0 (3.5)

5.0 (2.0)

4.0 (1.4)

(median (range))

19.0 (7-36)

15.0 (5-27)

10.0 (4-26)

8.0 (3-14)

7.5 (3-10)

5.0 (3-7)

4.0 (3-5)

Disease activity index

       

(mean (SD))

4.8 (1.3)

2.0 (1.2)

1.2 (1.2)

0.9 (1.0)

1.0 (1.3)

1.3 (1.4)

1.7 (1.8)

(median (range))

4.5 (3.5-7.0)

2.0 (0.5-3.5)

0.5 (0.5-3.5)

0.5 (0.5-3.0)

0.5 (0.5-3.0)

0.5 (0.5-3.0)

1.7 (0.5-3.0)

Disease severity index

       

(mean (SD))

10.5 (3.2)

8.3 (2.9)

7.2 (2.8)

6.2 (2.8)

6.7 (2.2)

7.7 (1.5)

8.5 (0.7)

(median (range))

11.0 (6-15)

7.0 (4-13)

6.0 (4-11)

6.0 (3-9)

7.0 (4-9)

8.0 (6-9)

8.5 (8-9)

HAQ

       

(mean (SD))

0.9 (0.7)

0.5 (0.5)

0.4 (0.5)

0.3 (0.7)

0.3 (0.6)

0.3 (0.6)

0.6 (0.6)

(median (range))

0.8 (0.1-2.4)

0.4 (0-1.6)

0.2 (0-1.5)

0 (0-1.5)

0 (0-1.2)

0 (0-1.1)

0 (0-1.3)

GH (mean (SD))

59.4 (20.9)

74.4 (16.5)

82.8 (16.6)

86.0 (10.8)

82.5 (21.8)

82.5 (17.7)

82.5 (17.7)

(median (range))

60.0 (30-85)

80.0 (50-95)

90.0 (50-95)

90.0 (70-95)

92.5 (50-95)

82.5 (70-95)

82.5 (70-95)

Blood CD20%

       

(mean (SD))

6.8 (3.9)

0.7 (1.5)

1.7 (2.4)

3.0 (2.7)

2.0 (1.6)

1.0 (1.5)

3.0 (3.3)

(median (range))

6.0 (2.5-14.7)

0.1 (0.1-4.6)

1.0 (0.1-7.0)

4.0 (0.3-7.0)

2.0 (0.2-3.0)

1.0 (0.2-3.0)

3.0 (0.3-5.0)

IgG mg/ml

       

(mean (SD))

1055 (233)

1001 (191)

1021 (158)

1028 (46.6)

946.2 (178)

944 (315)

951 (69)

(median (range))

1140 (729-1340)

932 (884-1440)

1030 (802-1220)

1005 (1000-1110)

938 (738-1170)

896 (656-1280)

951 (902-1000)

IgA mg/ml

       

(mean (SD))

184.0 (44.4)

174.5 (39.2)

177.8 (63.5)

179.4 (69.8)

152.5 (59.9)

139.0 (67.5)

100.0 (24.0)

(median (range))

183.5 (119-249)

183.5 (119-262)

200.0 (75-262)

168.5 (93-281)

154.0 (79-222)

136.0 (73-208)

100.0 (83-117)

IgM mg/ml

       

(mean (SD))

133.7 (21.7)

86.0 (12.8)

90.9 (28.9)

83.0 (18.7)

61.5 (6.7)

43.3 (10.6)

71.0 (1.4)

(median (range))

132.5 (95-157)

91.0 (56-136)

96.0 (40-136)

73.0 (64-105)

61.5 (54-69)

45.0 (32-53)

71.0 (70-72)

BAFF pg/ml

       

(mean (SD))

1233.5 (683.3)

1719.4 (1264.3)

3257.8 (1571.8)

2057.0 (912.5)

2988.0 (1804)

3520.0 (1999)

3608.0 (2824)

(median (range))

875.6 (683-2601)

1008.6 (356-4038)

3141.8 (723-6682)

1580.6 (1321.6-3280)

2406.2 (1534-5605)

3224.8 (1684-5651)

3608.0 (1610-5605)

IL6 pg/ml

       

(mean (SD))

3.7 (5.3)

1.0 (1.2)

0.6 (0.9)

0.4 (0.4)

1.2 (2.0)

0.1 (0.1)

0.1 (0.1)

(median (range))

1.7 (0.1-16.9)

0.1 (0.1-3.6)

0.1 (0.1-2.8)

0.4 (0.1-0.8)

0.25 (0.1-4.2

0.1 (0.1-0.1)

0.1 (0.1-0.1)

  1. Clinical and biological parameters of nine SSc patients treated with anti-CD20 at baseline, after 3, 6, 12, 18, 24 and 36 months. The values are indicated as the mean (SD) and median (range). All patients had trunk skin involvement.
  2. *Five SSc patients reached 12 months of follow up. **Four SSc patients reached 18 months of follow up. ***Three SSc patients reached 24 months of follow up. *****Two patients reached 36 months of follow up.
  3. BAFF, B-cell activating factor; GH, Global Health Status; HAQ, Health Assessment Questionnarie; Ig, immunoglobulin; SD, standard deviation; SSc, systemic sclerosis.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us